Source: Annual Congress 2008 - New age lung carcinogenesis: clinical impact



Rating:

Share or cite this content

Citations should be made in the following way:
P. Yang (Taipei, Taiwan, Province of China). Harvesting biomarkers for early risk assessment. Annual Congress 2008 - New age lung carcinogenesis: clinical impact

Member's Comments

No comment yet.

Related content which might interest you: Blood biomarker algorithms to guide COPD assessment and risk stratification Source: International Congress 2017 – Towards personalised medicine in COPD: biological and clinical phenotypes Year: 2017 Risk factors and biomarkers of low lung function in early adulthood in the Lifelines study Source: Virtual Congress 2021 – Asthma burden and management I Year: 2021 Are biomarkers helpful in sepsis for risk assessment or clinical trials? Source: Annual Congress 2011 - Molecular biomarkers at the bedside of critically ill patients Year: 2011 Physio-pathologic assessment to stratify risk Source: International Congress 2019 – PG14 Perioperative management of fragile patients undergoing major thoracic surgery Year: 2019 Non-invasive biomarkers for the evaluation of a patient at risk for lung cancer Source: Annual Congress 2013 –Early detection of lung cancer Year: 2013 Mortality risk prediction in COPD by a prognostic biomarker panel Source: Eur Respir J 2014; 44: 1557-1570 Year: 2014 Personalised prediction of future risk using early treatment response Source: International Congress 2017 – Primary care management of asthma and COPD Year: 2017 Risk stratification of pulmonary embolism: clinical evaluation, biomarkers or both? Source: Eur Respir J 2015; 46: 1551-1553 Year: 2015 Predicting risk of undiagnosed COPD: development and validation of the TargetCOPD score Source: Eur Respir J, 49 (6) 1602191; 10.1183/13993003.02191-2016 Year: 2017 Importance of admission biomarkers in prognostication of  patients with SARS-Cov-2 Source: Virtual Congress 2021 – COVID-19 and acute respiratory failure Year: 2021 Sputum induction for assessment of biomarkers in early development of new drugs for respiratory disease in a proof of concept setting Source: International Congress 2016 – Airway biomarkers Year: 2016 Issues other than tissue: non-invasive biomarkers of early stage lung cancer Source: Virtual Congress 2020 – Will the pulmonologist still play a role in the management of screen-detected pulmonary nodules? Year: 2020 Early detection of COPD using high risk detecting questionnaire Source: Eur Respir J 2006; 28: Suppl. 50, 449s Year: 2006 Determining the best diagnostic biomarker for sepsis and prognosis assessment Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012 Crossing the divide between clinical BOS risk prediction and proteomic BALF biomarkers Source: Annual Congress 2010 - Mechanisms of late allograft dysfunction: new insights Year: 2010 Longitudinal assessment of risk factors exposure and development of respiratory symptoms/diseases Source: Annual Congress 2008 - Epidemiology of respiratory symptoms and COPD Year: 2008 Occupational risk factors may be of importance to define populations suitable to screening of lung cancer Source: Annual Congress 2011 - Work, the environment and respiratory disease Year: 2011 Comparing non-invasive cardiovascular risk assessment tools in COPD patients: Validation with CV events Source: International Congress 2014 – Respiratory disease within hospital-based populations Year: 2014